Hikma stock heads into the open after a 2.8% drop
Published on 09/11/2026 at 08:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Hikma stock closed at GBP 14.98 on the London Stock Exchange on September 10, 2026, down 2.8% from the previous session. The shares moved within a session range that placed the close below the midpoint of their recent trading band, with the price also below analysts average target of GBP 20.01 reported the same day. In comparison, the FTSE 100 index finished September 10, 2026 down 0.57%, so Hikma stock weakened more than the broader blue chip benchmark in the last completed session.
September 10, 2026 in numbers
Hikma Pharmaceuticals PLC (ISIN GB00B128J450, LSE: HIK) saw its London listing end the September 10, 2026 session at GBP 14.98, representing a 2.8% decline on the day. Per summary data for large United Kingdom pharmaceuticals and biotech stocks, this closing level left Hikma stock about 9.8% lower than its level twelve months earlier and implied a market capitalization of roughly GBP 3.2 billion as of September 10, 2026. The same overview showed an analysts average target price of GBP 20.01, indicating the September 10, 2026 close stood materially below that consensus level. On the index side, the FTSE 100 ended September 10, 2026 at 10,608.92 points, down 0.57%, marking its fifth consecutive session of declines and underscoring that Hikma stock underperformed an already soft London market.
As Financial Times reported on September 10, 2026, Hikma advanced its epinephrine nasal spray program with multi market regulatory filings, signaling progress on a new formulation that could expand its emergency treatment portfolio. A related update carried by RTTNews noted that Hikma s United States over the counter listing HKMPY traded between USD 31.80 and USD 50.56 over the past year and closed the prior session at USD 41.31, framing the London performance within a wider international trading range. In the context of London, Euronext reported that elevated oil prices and inflation concerns weighed on the FTSE 100 on September 10, 2026, providing the broader market backdrop against which Hikma stock declined.
Dividend and regulatory focus today
Today, September 11, 2026, Hikma stock is set against a corporate calendar that includes a dividend payment date in the coming days. A United Kingdom dividends calendar for the next seven days shows Hikma Pharmaceuticals PLC flagged with a dividend payment date on September 17, 2026, indicating that the shares are approaching a distribution event that can influence trading around that time, as reported by shareprices.com. In parallel, the company s recent announcement on advancing epinephrine nasal spray through multi market regulatory filings, highlighted by Financial Times, remains a focal point for investors heading into today s London session as they assess regulatory progress and potential future revenue contributions.
